
Novo Nordisk's rapid growth has made company President and CEO Lars Fruergaard Jørgensen publically air thoughts of increasing the company's 2025 ambitions, which were set just 2 years ago.
This includes the firm's goals for its obesity business, which has received a boost with unprecedented demand for the weight loss drug Wegovy, and the enormous sales of the diabetes drug Ozempic have also brought Novo Nordisk considerably closer to reaching some of its big 2025 milestones.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app